First myostatin-targeted antibody approved for spinal muscular atrophy

RegulatoryapprovedPositive

AI Analysis

Summary

The first myostatin-targeted antibody has received FDA approval for the treatment of spinal muscular atrophy, representing a significant advance in therapeutic options for this neuromuscular disorder.

Outcome Details

First myostatin-targeted antibody approved for spinal muscular atrophy

Importance:8/10

Sentiment:

0.85

FDA approvalmyostatin inhibitorspinal muscular atrophyfirst-in-class

Related Companies

$RARE

Read the original article

Published by Nature Reviews Drug Discovery on September 18, 2026 12:00 AM

Read Original